ABOUT CENCORA
Cencora combines core pharmaceutical distribution with innovative business solutions to help our partners across the healthcare spectrum get medications to the patients who need them. Biopharmaceutical companies benefit from the global scale and resources of a company ranked #10 on the Fortune 500, combined with local expertise provided by more than 51,000 team members worldwide. Learn more at www.cencora.com.
Whether you are developing and commercializing small molecules, biologics, or advanced therapies, Cencora can provide the deep scientific, regulatory, and technical expertise you need across the product life cycle. Our regulatory affairs, operations, and CMC services help improve the speed, quality, and consistency of manufacturing through submissions and beyond to reduce risk and optimize product launches.
VIDEOS AND WEBINARS
-
![Cencora - CGT Payer Trends]( "Cell And Gene Therapies – U.S. Payer Trends")
Cell And Gene Therapies – U.S. Payer TrendsGain insights from U.S. payer interviews covering coverage processes, evidence requirements, and engagement strategies to accelerate market access from late-stage development through commercialization.
-
![Cencora - AI HEOR Market Access]( "The Transformative Potential Of AI In HEOR And Market Access")
The Transformative Potential Of AI In HEOR And Market AccessHEOR teams are under pressure to move faster without sacrificing rigor. Discover how AI accelerates evidence synthesis, fills data gaps, and supports living models that meet HTA transparency standards.
-
![Cencora - Evolving Policy Landscape]( "The Evolving Policy Landscape: U.S. And EU Pricing And Access")
The Evolving Policy Landscape: U.S. And EU Pricing And AccessU.S. and EU policy shifts are reshaping pricing, access, and launch strategy. Hear expert analysis on IRA, MFN, 340B, EU HTA Regulation, and the Biotech Act to stay ahead of 2025-2026 changes.
-
![Foundations And Implications For International Reference Pricing]( "Foundations And Implications For International Reference Pricing")
Foundations And Implications For International Reference PricingReforms like the U.S. Most Favored Nation model are intensifying pressure on global launch strategies. Understand the tactics that protect value while expanding access.
-
![The Growing Role Of Real-World Evidence]( "The Growing Role Of Real-World Evidence")
The Growing Role Of Real-World EvidenceRegulators and HTA bodies are raising the bar on real-world evidence. Understand how JCAs, oncology registries, and EHR data are redefining what credible RWE looks like, and how to meet agency expectations.
-
![GettyImages-2149321181 colleagues, meeting]( "Integrated Quality, Regulatory, And Safety Services")
Integrated Quality, Regulatory, And Safety ServicesA single-vendor model for quality, regulatory, and safety services provides consistent project management and cost-effective scalability. Hear how integrated solutions support market entry and growth.
CONTACT INFORMATION
Cencora
1 W 1st Ave.
Conshohocken, PA 19428
UNITED STATES
FEATURED INSIGHTS
-
![GettyImages-1451133080 meeting, strategy]( "Overcoming Regulatory, Pharmacovigilance, And Market Access Roadblocks To European Expansion")
With 30 national HTA bodies, an EU-QPPV requirement, and MFN pricing now linking European reimbursement rates to U.S. drug prices, launching in Europe demands a coordinated global strategy.
-
![Business meeting-GettyImages-1317387050]( "Competing Through Complexity: Models To Manage Mature Products")
As patented drug revenues drop from 23% to just 10% by 2034, biopharma leaders need a clear framework for matching mature product strategy to their organization's operating model and risk appetite.
-
![GettyImages-2024666721-meeting-table-office-business-man-doctors]( "Closing The Readiness Gap For CGTs In Community-Based Care")
Only one in five eligible cell and gene therapy patients receives treatment. Expanding access into community hospitals requires overcoming significant operational and readiness barriers.
-
![Business meeting-GettyImages-2209242819]( "How To Effectively Manage Local Affiliate Pharmacovigilance Outsourcing")
Managing PV across dozens of markets strains even experienced safety teams. Learn about a framework that helps you maintain compliance, reduce risk, and scale confidently into new markets.
-
![GettyImages-2150364155-hand-digital-documents-validation]( "Mid-Sized Pharma Optimizes Local Affiliate Safety Operations")
Managing local affiliate PV strains any team. See how a mid-sized biopharma standardized ICSR processing across 94 countries, improved compliance tracking, and achieved centralized oversight.
LEARN MORE ABOUT OUR SOLUTIONS
-
![GettyImages-1136666580 checklist]( "What To Look For In A Commercialization Partner")
From closing evidence gaps with real-world studies to coordinating payer engagement and patient adherence support, the right pre-launch partner does far more than manage logistics. Here's what to look for.
-
![GettyImages-891264822 planning, meeting]( "The Benefits Of Engaging In Pre-Approval Information Exchange (PIE)")
Explore the top 3 insights on the impact of pre-approval communication and learn why healthcare decision makers want more pre-approval resources and engagement from manufacturers.
-
![GettyImages-2198078409 - meeting]( "Five Key Factors For Sustained Post‑Launch Success")
From payer negotiations and formulary expansion to real-time uptake analytics and global distribution, post-launch success depends on a commercialization partner that adapts as market conditions shift.
WHITE PAPERS
-
![Business meeting-GettyImages-1317387050]( "Competing Through Complexity: Models To Manage Mature Products")
Competing Through Complexity: Models To Manage Mature ProductsAs patented drug revenues drop from 23% to just 10% by 2034, biopharma leaders need a clear framework for matching mature product strategy to their organization's operating model and risk appetite.
-
![Business meeting-GettyImages-2209242819]( "How To Effectively Manage Local Affiliate Pharmacovigilance Outsourcing")
How To Effectively Manage Local Affiliate Pharmacovigilance OutsourcingManaging PV across dozens of markets strains even experienced safety teams. Learn about a framework that helps you maintain compliance, reduce risk, and scale confidently into new markets.
-
![iStock-1200038380-stock-finance-chart-CFO]( "International Reference Pricing (IRP): Foundations, Shifts, And What To Do Next")
International Reference Pricing (IRP): Foundations, Shifts, And What To Do NextAs global pricing reforms evolve and policies gain traction, stakeholders must critically reassess the role of International Reference Pricing in balancing affordability, access, and incentives for innovation.
